The sound of chatter and wind instruments being blown at different times fills the room at the Launceston College music centre as the band members warm up for rehearsals.

It has been three years in the making: Justyn Atkins from Launceston is now putting the finishing touches on his trusty ute in preparation for the 2015 Deni Ute Muster.

It's been two years in construction at a cost of $91.3 million but the first phase of the redevelopment of Dubbo Base Hospital is about to open.

The economic impact of the pandemic on Australia's regional towns and cities is varied, but with a smaller population base, the path back to recovery is likely to be longer and harder for many.

A property search fails to uncover the remains of missing man Michael Purse, but SA Police say two men they suspect of murdering him are already in custody for unrelated crimes.

The State Government has been defeated in a key piece of legislation which could have a major impact on its ability to win a second term in 2022, and it's not land tax, writes Casey Briggs.

The coronavirus pandemic has made life harder for most people, but spare a thought for 66-year-old Isabel McLeary, who is looking after three teenagers with disability who can now only access vital support online.

The curve is flattening, the growth factor is below one, but is it still too early to ease coronavirus restrictions? We asked four health experts what Australia should be doing next.

Prickles the merino sheep has been on the run from her Dunalley farm since the 2013 Tasmanian bushfires, but now she's out of self-isolation and ready for a trim.

A woman whose house burnt down in bushfires affecting the NSW North Coast said that she and her husband now plan on leaving the bush due to the hazard.

While you hear about children choosing the same career as their parents regularly, the opposite is true for this mother-daughter police duo.

An app designed to alert South Australians about bushfires is still not ready as total fire bans were issued amid sweltering temperatures. A watch and act message has been issued for a fire burning near Swan Reach in the state's Murraylands region.

Australia is the last inhabited continent on Earth that is free of the varroa mite, a parasite which has crippled honey bees everywhere it has taken hold. The threat is real but our beekeepers are preparing to meet it head on.

A self-funded engineer was 12 kilometres short of his goal of reaching space at a recent attempt in the middle of Australia's Outback.

Researchers say an online tool to help understand where Australia's Bogong moths have disappeared to is starting to show promising results.

Grant 'Scooter' Patterson may be half as tall as most people but he does not do things by halves. He works hard, plays hard and pushes himself in the pool, chasing his dream of winning a Paralympic medal.

Authorities say complacent city dwellers need to learn from their regional cousins and have an emergency kit ready for when a natural disaster strikes, including three days' worth of water.

Epson UK has launched ReadyPrint, its first subscription printing service for its consumer cartridge printer models.

Lambs have died of hypothermia and orchards are ready for a fruitful spring following a snow event in regional New South Wales.

HTML5 is the fifth version of the World Wide Web Hypertext Markup Language (HTML). HTML5 accessibility is a work in progress with many details still under development.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) investors will be delighted, with the company turning in some strong...

Singing Songwriter Ahmad Formally "thisisjavon" Is Ready To Strike A Pose For The Camera And Get Sexy For A Same-Sex Bachelors

Rockies all-star shortstop Trevor Story pays close attention to the reports about baseball's possible return in the midst of the coronavirus pandemic.

Rockies all-star shortstop Trevor Story pays close attention to the reports about baseball's possible return in the midst of the coronavirus pandemic.

About 6,500 athletes who already have earned their spots for the Tokyo Games are in for 2021 under redrawn qualifying regulations published Tuesday by the International Olympic Committee.

Rockies all-star shortstop Trevor Story pays close attention to the reports about baseball's possible return in the midst of the coronavirus pandemic.

Tales premieres on July 2 at 9/8c.

There is 14K gold involved, of course.

She's launching a collection with British brand Lipsy.

Tales premieres on July 2 at 9/8c.

The raptress opens up about her marriage.

You may recall in the early days of the pandemic, that pharma giant Gilead Sciences -- which has been accused of price gouging and (just last year!) charging exorbitant prices on drug breakthroughs developed with US taxpayer funds -- was able to sneak through an orphan works designation for its drug remdesevir for COVID-19 treatment. As we pointed out, everything about this was insane, given that orphan works designations, which give extra monopoly rights to the holders (beyond patent exclusivity), are meant for diseases that don't impact a large population. Gilead used a loophole: since the ceiling for infected people to qualify for orphan drug status is 200,000, Gilead got in its application bright and early, before there were 200,000 confirmed cases (we currently have over 1.3 million). After the story went, er... viral, Gilead agreed to drop the orphan status, realizing the bad publicity it was receiving.

After a brief dalliance with chloroquine, remdesivir has suddenly been back in demand as the new hotness of possible COVID-19 treatments. Still, a close reading of the research might give one pause. There have been multiple conflicting studies, and Gilead's own messaging has been a mess.

On April 23, 2020, news of the study’s failure began to circulate. It seems that the World Health Organization (WHO) had posted a draft report about the trial on their clinical trials database, which indicated that the scientists terminated the study prematurely due to high levels of adverse side effects.

The WHO withdrew the report, and the researchers published their results in The Lancet on April 29, 2020.

The number of people who experienced adverse side effects was roughly similar between those receiving remdesivir and those receiving a placebo. In 18 participants, the researchers stopped the drug treatment due to adverse reactions.

But then...

However, also on April 29, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that their NIH trial showed that remdesivir treatment led to faster recovery in hospital patients with COVID-19, compared with placebo treatment.

“Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo,” according to the press release. “Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.”

The mortality rate in the remdesivir treatment group was 8%, compared with 11.6% in the placebo group, indicating that the drug could improve a person’s chances of survival. These data were close to achieving statistical significance.

And then...

“In addition, there is another Chinese trial, also stopped because the numbers of new patients with COVID-19 had fallen in China so they were unable to recruit, which has not yet published its data,” Prof. Evans continues. “There are other trials where remdesivir is compared with non-remdesivir treatments currently [being] done and results from some of these should appear soon.”

Gilead also put out its own press release about another clinical trial, which seems more focused on determining the optimal length of remdesivir treatment. Suffice it to say, there's still a lot of conflicting data and no clear information on whether or not remdesevir actually helps.

Still, that hasn't stopped people from trying to figure out just how much Gilead will price gouge going forward:

The Institute for Clinical and Economic Review (ICER), which assesses effectiveness of drugs to determine appropriate prices, suggested a maximum price of $4,500 per 10-day treatment course based on the preliminary evidence of how much patients benefited in a clinical trial. Consumer advocacy group Public Citizen on Monday said remdesivir should be priced at $1 per day of treatment, since “that is more than the cost of manufacturing at scale with a reasonable profit to Gilead.”

Some Wall Street investors expect Gilead to come in at $4,000 per patient or higher to make a profit above remdesivir’s development cost, which Gilead estimates at about $1 billion.

So... we've got a range of $10 to $4,500 on a treatment that we don't yet know works, and which may or may not save lives. But, given that we're in the midst of a giant debate concerning things like "reopening the economy" -- something that can really only be done if the public is not afraid of dying (or at least becoming deathly ill) -- the value to the overall economy seems much greater than whatever amount Gilead wants to charge. It seems the right thing to do -- again, if it's shown that remdesevir actually helps -- is to just hand over a bunch of money to Gilead, say "thank you very much" and get the drug distributed as widely as possible. Though, again, it should be noted that a decent chunk of the research around remdesevir was not done or paid for by Gilead, but (yet again) via public funds to public universities, which did the necessary research. The idea that it's Gilead that should get to reap massive rewards for that seems sketchy at best. But the absolute worst outcome is one in which Gilead sticks to its standard operating procedure and prices the drug in a way that millions of Americans can't afford it, and it leads to a prolonging/expanding of the pandemic.

Even though Corporate America has anointed Hillary Clinton as its next President, Senator Bernie Sanders' populist message is already in a week's time raising individual contributions totaling millions of dollars from hundreds of thousands of people! Continue reading →

Green Party's Jill Stein says that what we Fear from Donald Trump is what we have already seen from Hillary Clinton. Continue reading →

While marketing and sales professionals increasingly find themselves drowning in data, a new IBM study finds that nearly two thirds—64 percent--of surveyed CMOs and sales leaders believe their industries will be ready to adopt cognitive technologies in the next three years. However despite this stated readiness, the study finds that only 24 percent of those surveyed believe they have strategy in place to implement these technologies today.

Guy 1: Cleaning gutters with a leaf blower. Guy 2: Holding him up with JUMPER CABLES.

Note: Written and illustrated months before, well, everything happened.

Although nothing can truly replace this show, there are other comedies out there that might ease the pain even just a little bit. READ MORE...